Abstract:Fragile X syndrome (FXS) is the most common genetic cause of intellectual disability and the most common single-gene cause of autism. It is caused by mutations on the fragile X mental retardation gene (FMR1) and lack of fragile X mental retardation protein, which in turn, leads to decreased inhibition of translation of many synaptic proteins. The metabotropic glutamate receptor (mGluR) hypothesis states that the neurological deficits in individuals with FXS are due mainly to downstream consequences of overstimulation of the mGluR pathway. The main efforts have focused on mGluR5 targeted treatments; however, investigation on the gamma-aminobutyric acid (GABA) system and its potential as a targeted treatment is less emphasized. The fragile X mouse models (Fmr1-knock out) show decreased GABA subunit receptors, decreased synthesis of GABA, increased catabolism of GABA, and overall decreased GABAergic input in many regions of the brain. Consequences of the reduced GABAergic input in FXS include oversensitivity to sensory stimuli, seizures, and anxiety. Deficits in the GABA receptors in different regions of the brain are associated with behavioral and attentional processing deficits linked to anxiety and autistic behaviors. The understanding of the neurobiology of FXS has led to the development of targeted treatments for the core behavioral features of FXS, which include social deficits, inattention, and anxiety. These symptoms are also observed in individuals with autism and other neurodevelopmental disorders, therefore the targeted treatments for FXS are leading the way in the treatment of other neurodevelopmental syndromes and autism. The GABAergic system in FXS represents a target for new treatments. Herein, we discuss the animal and human trials of GABAergic treatment in FXS. Arbaclofen and ganaxolone have been used in individuals with FXS. Other potential GABAergic treatments, such as riluzole, gaboxadol, tiagabine, and vigabatrin, will be also discussed. Further studies are needed to determine the safety and efficacy of GABAergic treatments for FXS.

The safety and efficacy of metformin in fragile X syndrome: An open-label study

Metformin treatment in young children with fragile X syndrome

Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders

Metformin as targeted treatment in fragile X syndrome

Longitudinal follow-up of metformin treatment in Fragile X Syndrome

Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology

Metformin ameliorates core deficits in a mouse model of fragile X syndrome

Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases

Blood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome

Novel presynaptic assay system revealed that metformin ameliorates exaggerated synaptic release and Munc18-1 accumulation in presynapses of neurons from Fragile X syndrome mouse model

A therapy for FXS?

Neurophysiological effects of a combined treatment of lovastatin and minocycline in patients with fragile X syndrome: Ancillary results of the LOVAMIX randomized clinical trial

New Targeted Treatments for Fragile X Syndrome

Modulation of the GABAergic pathway for the treatment of fragile X syndrome

Elevated de novo protein synthesis in FMRP-deficient human neurons and its correction by metformin treatment

State‐of‐the‐art therapies for fragile X syndrome

Therapeutic efficacy of the BKCa channel opener chlorzoxazone in a mouse model of Fragile X syndrome

Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder

Targeted Treatments for Fragile X Syndrome

Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence

Proteomics insights into fragile X syndrome: Unraveling molecular mechanisms and therapeutic avenues